Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidinesbased chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)

被引：0
|
作者：
Damato, A. [1 ]
Bilancia, D. [2 ]
Iachetta, F. [1 ]
Strippoli, A. [3 ]
Filiali, F. [4 ]
Casaretti, R. [5 ]
Bernardini, I. [6 ]
Bellotti, G. [7 ]
Frassineti, G. L. [8 ]
Di Fabio, F. [9 ]
Aieta, M. [10 ]
Ghidini, M. [11 ]
Trentin, C. [12 ]
Cardellino, G. [13 ]
Gervasi, E. [1 ]
Romagnani, A. [1 ]
Cinieri, S. [14 ]
Normanno, N. [15 ]
Boni, L. [16 ]
Pinto, C. [1 ]
机构：
[1] Azienda USL IRCCS Reggio Emilia, Ctr Comprehens Canc, Oncol & Tecnol Avanzate, Med Oncol, Reggio Emilia, Italy
[2] Az Osped San Carlo, Oncol, Potenza, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol, Rome, Italy
[4] ASST Brianza, Vimercate Hosp, Oncol, Vimercate, Italy
[5] Ist Nazl Tumori IRCCS Fdn G Pascale, Expt Clin Abdominal Oncol Unit, Naples, Italy
[6] Osped Ramazzini, Oncol, Carpi, Italy
[7] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Oncol Unit, Oncol, Alessandria, Italy
[8] IRST Ist Romagnolo Tumori Dino Amadori IRCCS Srl, Oncol, Meldola, Italy
[9] AOU Policlin S Orsola Malpighi, Oncol, Bologna, Italy
[10] IRCCS CROB, Oncol Unit, Rionero In Vulture, Italy
[11] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Day Hosp Oncol, Milan, Italy
[12] Osped Santa Chiara APSS, Dept Med Oncol, Trento, Italy
[13] Azienda Sanitaria Univ Friuli Centrale, Oncol, Udine, Italy
[14] Osped A Perrino, Dept Med Oncol, Brindisi, Italy
[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Translat Res Dept, Naples, Italy
[16] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421P
引用
收藏
页码：S171 / S171
页数：1
相关论文
共 50 条
  • [31] RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.
    Xu, Rui-hua
    Zhang, Yan-Qiao
    Pan, Hongming
    Feng, Ji Feng
    Zhang, Tao
    Liu, Tianshu
    Qin, Yanru
    Han, Rubing
    Zhang, Wanli
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.
    Lee, Keun Wook
    Bai, Li-Yuan
    Jung, Minkyu
    Ying, Jieer
    Im, Young Hyuck
    Oh, Do-Youn
    Cho, Jae Yong
    Oh, Sang Cheul
    Chao, Yee
    Li, Huiyan
    Zhou, Ping
    Bao, Yuanyuan
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] HLX22 plus HLX02 and XELOX as first-line therapy for HER2positive advanced gastric/gastroesophageal junction cancer: Updated results from a randomized, double-blind phase II study
    Li, J.
    Gao, Y.
    Li, N.
    Qiu, M.
    Zhang, Y.
    Yang, M.
    Lu, L.
    Li, W.
    Ma, Y.
    Hou, X.
    Sun, G.
    Cai, M.
    Wang, J.
    Lu, J.
    Zhong, D.
    Yang, F.
    Yu, H.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S171 - S172
  • [34] Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC)
    Catenacci, Daniel
    Rosales, Minori
    Wigginton, Jon
    Chung, Hyun Cheol
    Yoon, Harry
    Shen, Lin
    Kang, Yoon-Koo
    Moehler, Markus
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [35] Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
    Wainberg, Zev A.
    Enzinger, Peter C.
    Kang, Yoon-Koo
    Yamaguchi, Kensei
    Qin Shukui
    Lee, Keun-Wook
    Oh, Sang Cheul
    Li Jin
    Turk, Haci Mehmet
    Teixeira, Alexandra Carolina
    Cardellino, Giovanni Gerardo
    Guardeno, Raquel
    Mitra, Siddhartha
    Yang Yingsi
    Collins, Helen
    Catenacci, Daniel V. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Liu, Funan
    Gong, Jifang
    Jin, Zhaoyu
    Zhang, Miao
    Zhang, Shu
    Zhang, Yanqiao
    Liang, Xinjun
    Li, Yun
    Yang, Xiaochun
    Yang, Yaping
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC)
    Shah, Manish A.
    Xu, Ruihua
    Bang, Yung-Jue
    Hoff, Paulo M.
    Liu, Tianshu
    Herraez-Baranda, Luis A.
    Xia, Fan
    Garg, Amit
    Shing, Mona
    Tabernero, Josep
    CANCER RESEARCH, 2016, 76
  • [38] A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer
    Ji, Jiafu
    Shen, Lin
    Gao, Xiangyu
    Ji, Ke
    Chen, Ye
    Xu, Nong
    Liu, Tianshu
    Yang, Nong
    Zhong, Haijun
    Li, Ziyu
    Li, Changzheng
    Guo, Zengqing
    Fan, Qingxia
    Lin, Xiaoyan
    Yao, Zhifang
    Liu, Wei
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+gastroesophageal junction (GEJ) or gastric cancer (GC)
    Catenacci, Daniel V. T.
    Rosales, Minori Koshiji
    Wigginton, Jon M.
    Chung, Hyun Cheol
    Yoon, Harry H.
    Shen, Lin
    Moehler, Markus H.
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
    Lordick, F.
    Shitara, K.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Aprile, G.
    Xu, J.
    Chao, J.
    Pazo-Cid, R.
    Kang, Y. K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
12345